论文部分内容阅读
[目的]探讨健择联合顺铂治疗蒽环类和(或)紫杉类化疗后的复发性乳腺癌。[方法]34例经蒽环类和(或)紫杉类化疗后的复发性乳腺癌患者,采用健择1000mg/m2,第1d、8d静脉滴注;顺铂80mg/m2,第8d静脉滴注,3～4周为1个疗程。所有病例均化疗4个疗程以上。[结果]完全缓解(CR)2例,部分缓解(PR)14例,有效率47.06%(16/34)。主要毒副反应为白细胞及血小板减少。[结论]健择联合顺铂治疗蒽环类和(或)紫杉类耐药复发性乳腺癌疗效高,毒副反应可耐受。
[Objective] To explore the combination of gemcitabine and cisplatin in the treatment of recurrent breast cancer after anthracycline and (or) taxane chemotherapy. [Methods] Thirty-four patients with recurrent breast cancer after anthracycline and / or taxane chemotherapy were treated with intravenous infusion of Gemcitabine 1000mg / m2 on day 1 and 8; cisplatin 80mg / m2 on day 8 Note, 3 to 4 weeks for a course of treatment. All cases were chemotherapy for more than 4 courses. [Results] Two patients had complete remission (CR) and 14 had partial remission (PR), the effective rate was 47.06% (16/34). The main side effects of white blood cells and thrombocytopenia. [Conclusion] Combination of gemcitabine and cisplatin in the treatment of anthracycline and (or) taxane-resistant recurrent breast cancer has high curative effect and tolerable side effects.